Details of the Drug

General Information of Drug (ID: DMY0KGJ)

Drug Name

Chlorprothixene

Synonyms

Chloroprothixene; Chlorprothixen; Chlorprothixenum; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Clorprotisene; Clorprotixeno; Iaractan; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm; Clorprotisene [DCIT]; MK 184; N 714; N 714C; NCI56378; Alpha-Chlorprothixene; Chlorprothixenum [INN-Latin]; Cis-Chlorprothixene; Clorprotixeno [INN-Spanish]; N-714; Ro 4-0403; Taractan (TN); Truxal (TN); Ro-4-0403;Trans(E)-Chlorprothixen; Chlorprothixene (JAN/USAN/INN); Chlorprothixene [USAN:INN:BAN:JAN]; Cloxan, Taractan, Truxal, Chlorprothixene; Cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-(8CI); (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; (alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Psychotic disorder	6A20-6A25	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antipsychotic Agents

Affected Organisms

Humans and other mammals

ATC Code

N05AF03: Chlorprothixene

N05AF: Thioxanthene derivatives

N05A: ANTIPSYCHOTICS

N05: PSYCHOLEPTICS

N: NERVOUS SYSTEM

N05AF03: Chlorprothixene

N05AF: Thioxanthene derivatives

N05A: ANTIPSYCHOTICS

N05: PSYCHOLEPTICS

N: NERVOUS SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

315.9

Logarithm of the Partition Coefficient (xlogp)

5.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 11.5 mL/min/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 - 12 hours [2]
Metabolism: The drug is metabolized via the hepatic []
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 13.7 L/kg [2]

Chemical Identifiers

Formula: C18H18ClNS
IUPAC Name: (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
Canonical SMILES: CN(C)CC/C=C\\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
InChI: InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
InChIKey: WSPOMRSOLSGNFJ-AUWJEWJLSA-N

Cross-matching ID

PubChem CID: 667467
ChEBI ID: CHEBI:50931
CAS Number: 113-59-7
UNII: 9S7OD60EWP
DrugBank ID: DB01239
TTD ID: D0B0CP
VARIDT ID: DR00591

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[4]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Protein Interaction/Cellular Processes	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Psychotic disorder

ICD Disease Classification

6A20-6A25

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016149.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42.
4	Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
5	Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther. 1999 Nov;291(2):547-54.